Furumai Ryohei, Matsuyama Akihisa, Kobashi Nobuyuki, Lee Kun-Hyung, Nishiyama Makoto, Nakajima Hidenori, Tanaka Akito, Komatsu Yasuhiko, Nishino Norikazu, Yoshida Minoru, Horinouchi Sueharu
Department of Biotechnology, The University of Tokyo, Tokyo 113-8657, Japan.
Cancer Res. 2002 Sep 1;62(17):4916-21.
FK228 is a histone deacetylase (HDAC) inhibitor, the molecular mechanism of inhibition of which has been unknown. Here we show that reduction of an intramolecular disulfide bond of FK228 greatly enhanced its inhibitory activity and that the disulfide bond was rapidly reduced in cells by cellular reducing activity involving glutathione. Computer modeling suggests that one of the sulfhydryl groups of the reduced form of FK228 (redFK) interacts with the active-site zinc, preventing the access of the substrate. HDAC1 and HDAC2 were more strongly inhibited by redFK than HDAC4 and HDAC6. redFK was less active than FK228 in inhibiting in vivo HDAC activity, due to rapid inactivation in medium and serum. Thus, FK228 serves as a stable prodrug to inhibit class I enzymes and is activated by reduction after uptake into the cells. The glutathione-mediated activation also implicates its clinical usefulness for counteracting glutathione-mediated drug resistance in chemotherapy.
FK228是一种组蛋白去乙酰化酶(HDAC)抑制剂,其抑制的分子机制尚不清楚。在此我们表明,FK228分子内二硫键的还原极大地增强了其抑制活性,并且该二硫键在细胞中通过涉及谷胱甘肽的细胞还原活性而迅速被还原。计算机模拟表明,FK228还原形式(redFK)的一个巯基与活性位点锌相互作用,阻止底物进入。与HDAC4和HDAC6相比,redFK对HDAC1和HDAC2的抑制作用更强。由于在培养基和血清中迅速失活,redFK在抑制体内HDAC活性方面比FK228活性更低。因此,FK228作为一种稳定的前药来抑制I类酶,并在被细胞摄取后通过还原而被激活。谷胱甘肽介导的激活也暗示了其在化疗中对抗谷胱甘肽介导的耐药性的临床应用价值。